Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy.
Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells.
Through the agreement, the two companies plan to cooperate in the fields of basic research on anti-cancer drug development, development of new anti-cancer drug candidates, technology transfer and commercialization using Cyrus Therapeutics’ technologies.